News stories about CONMED Corporation (NASDAQ:CNMD) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CONMED Corporation earned a news impact score of 0.03 on Accern’s scale. Accern also assigned headlines about the medical technology company an impact score of 47.7668735312736 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- $187.21 Million in Sales Expected for CONMED Corporation (NASDAQ:CNMD) This Quarter (americanbankingnews.com)
- “Tank”: Walcott And Wenger Gush Over Arsenal’s New Signing (fishinghd.com)
- Analysts Expect CONMED Corporation (CNMD) to Post $0.41 Earnings Per Share (americanbankingnews.com)
- CONMED Corporation (CNMD) Ownership Up in Latest Report from Victory Capital Management Inc (highlightpress.com)
- Reviewing CONMED Corporation (CNMD) and Asante Solutions (PUMP) (americanbankingnews.com)
Shares of CONMED Corporation (CNMD) traded down 0.30% on Friday, reaching $49.26. 34,310 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $50.42 and a 200 day moving average of $47.24. CONMED Corporation has a one year low of $37.60 and a one year high of $52.82. The firm has a market capitalization of $1.38 billion, a P/E ratio of 88.12 and a beta of 0.67.
CONMED Corporation (NASDAQ:CNMD) last announced its earnings results on Wednesday, July 26th. The medical technology company reported $0.41 EPS for the quarter, meeting analysts’ consensus estimates of $0.41. The business had revenue of $197.20 million for the quarter, compared to analysts’ expectations of $194.50 million. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The company’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.47 EPS. On average, equities research analysts predict that CONMED Corporation will post $1.87 EPS for the current year.
CNMD has been the topic of a number of recent analyst reports. BidaskClub lowered shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Zacks Investment Research lowered shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Needham & Company LLC upped their price target on shares of CONMED Corporation from $48.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, April 27th. Ladenburg Thalmann Financial Services lowered shares of CONMED Corporation from a “buy” rating to a “neutral” rating and cut their price target for the company from $50.00 to $48.00 in a research note on Thursday, April 27th. Finally, TheStreet upgraded shares of CONMED Corporation from a “c+” rating to a “b-” rating in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. CONMED Corporation has an average rating of “Hold” and a consensus price target of $49.33.
In other CONMED Corporation news, Director Dirk Kuyper sold 1,000 shares of the business’s stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $52.24, for a total transaction of $52,240.00. Following the sale, the director now directly owns 10,739 shares in the company, valued at approximately $561,005.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Jonas sold 3,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $51.22, for a total transaction of $153,660.00. Following the sale, the executive vice president now owns 14,455 shares in the company, valued at $740,385.10. The disclosure for this sale can be found here. Company insiders own 2.62% of the company’s stock.
CONMED Corporation Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
